Clinical TrialJun 17, 2026, 08:06 AM
Elicio Therapeutics Reports Multiple Complete Responses in Pancreatic Cancer
AI Summary
Elicio Therapeutics reported preliminary clinical observations from its Phase 2 AMPLIFY-7P study, showing multiple complete responses in patients with metastatic mKRAS pancreatic cancer. Three patients who progressed on ELI-002 7P subsequently achieved 100% confirmed complete radiographic and metabolic responses after receiving nivolumab-based therapy. The company believes these observations support the evaluation of ELI-002 7P in combination with checkpoint inhibition and plans to initiate a Phase 1 study in first-line metastatic mKRAS PDAC, subject to funding. Complete responses are historically rare in this patient population.
Key Highlights
- 100% confirmed complete radiographic and metabolic responses in three patients with metastatic mKRAS pancreatic cancer.
- Responses observed after ELI-002 7P treatment and subsequent nivolumab-based therapy.
- Complete responses are rarely (0-8%) observed in metastatic pancreatic cancer in published studies.
- ELI-002 7P-induced mutant KRAS-specific T cells may synergize with checkpoint inhibition.
- Elicio plans to initiate a Phase 1 study in first-line metastatic mKRAS PDAC, subject to funding.
- A virtual Key Opinion Leader event is scheduled for June 24, 2026, at 1:00 PM ET to discuss observations.
Price Impact
More from ELTX